Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction

Koren, Ofir; Azaizah, Mohamed; Rozner, Ehud; Elias, Mazen; Turgeman, Yoav

doi:10.1007/s11239-019-01996-6

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, the levels of hs-cTnI significantly correspond to the presence and components of metabolic syndrome [78]. No significant difference was found in changes in hs-cTnT/I between non-ST elevation myocardial infarction patients with and without T2DM [79,80]. However, elevated hs-Tnl levels were found to be independent predictors of MACE in individuals with known CAD regardless of glucose metabolism status [46,79,81,82] as well as among patients with prediabetes and T2DM without known CAD [83,84].…”

Section: Cardiac Troponinsmentioning

confidence: 99%

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Berezin

2020

Diabetes Ther

View full text Add to dashboard Cite

The aim of this narrative review is to update the current knowledge on the differential choice of circulating cardiac biomarkers in patients with prediabetes and established type 2 diabetes mellitus (T2DM). There are numerous circulating biomarkers with unconfirmed abilities to predict clinical outcomes in pre-DM and DM individuals; the prognostication ability of the cardiac biomarkers reported here has been established, and they are still being studied. The conventional cardiac biomarkers, such as natriuretic peptides (NPs), soluble suppressor tumorigenisity-2, high-sensitivity circulating cardiac troponins and galectin-3, were useful to ascertain cardiovascular (CV) risk. Each cardiac biomarker has its strengths and weaknesses that affect the price of usage, specificity, sensitivity, predictive value and superiority in face-to-face comparisons. Additionally, there have been confusing reports regarding their abilities to be predictably relevant among patients without known CV disease. The large spectrum of promising cardiac biomarkers (growth/differential factor-15, heart-type fatty acid-binding protein, cardiotrophin-1, carboxy-terminal telopeptide of collagen type 1, apelin and noncoding RNAs) is discussed in the context of predicting CV diseases and events in patients with known prediabetes and T2DM. Various reasons have been critically discussed related to the variable findings regarding biomarker-based prediction of CV risk among patients with metabolic disease. It was found that NPs and hs-cTnT are still the most important tools that have an affordable price as well as high sensitivity and specificity to predict clinical outcomes among patients with pre-DM and DM in routine clinical practice, but other circulating biomarkers need to be carefully investigated in large trials in the future.

show abstract

Section: Cardiac Troponinsmentioning

confidence: 99%

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Berezin

2020

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…при ИМ [20,21]. Существует мнение, что развитие ФП может потенцировать тромбин, уровень которого повышается при ИМ [22][23][24]. Этот эффект реализуется посредством взаимодействия тромбина с рецепторами PAR-1 (Protease-activated receptors 1).…”

unclassified

Pathogenesis and clinical significance of atrial fibrillation in myocardial infarction

Зыков¹,

Барбараш²

2021

Russ J Cardiol

View full text Add to dashboard Cite

Currently, there is no information in novel clinical guidelines on the importance of active detection of atrial fibrillation (AF) in myocardial infarction (MI), as well as on the management of such patients. The aim of this review was to present actual information about possible risk factors, features of pathogenesis, as well as the prognostic significance of AF in MI. Analysis of the literature has shown that many researchers divide AF into new-onset AF (developed after MI) and chronic AF (existing in history before MI). New-onset AF is common complication in MI according to different studies (from 3 to 28% among all patients with MI), which is associated with death and cardioembolic events. Moreover, in every third patient with MI, AF is asymptomatic, which makes it extremely urgent to develop special algorithms aimed at its active search.

show abstract

Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST‐elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI)

Cao

2020

Drug Development Research

View full text Add to dashboard Cite

ObjectiveTo conduct a randomized double‐blind prospective study to investigate effect of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST‐elevation AMI after PCI.MethodsOne hundred and ninety‐two AMI patients over 60 years old who underwent PCI were randomly divided into six groups: the low atorvastatin group, high atorvastatin group; low rosuvastatin group; high rosuvastatin group; low simvastatin group; high simvastatin group. Demographic data and clinical information as well as coronary angiography parameters were recorded. Plasma levels of CK‐MB, BNP, ALT, and TnI were measured at 12 hr, 24 hr, and 1 week after PCI. Major cardiovascular events (MACE) were recorded and analyzed using Kaplan–Meier (K‐M) curve.ResultsNo significant differences were observed in angiographic and procedural characteristics. In all high dose groups, all levels of CK‐MB, BNP, ALT, and TnI were significantly lower. However, after 1 week of PCI, only CK‐MB, BNP, and TnI showed significant difference between high and low dose groups. Patients in high dose groups had significantly lower rates for surgical or percutaneous intervention, recurrence of angina, and rehospitalization. K–M curve analysis also showed cumulative incidence freedom time of overall MACE in high dose groups was significantly longer. No significant differences were found among different drugs with the same doses.ConclusionPatients with higher doses had lower level of CK‐MB, BNP, ALT, and TnI and lower occurrence of MACE after PCI.

show abstract

Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction

Cited by 5 publications

References 18 publications

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Pathogenesis and clinical significance of atrial fibrillation in myocardial infarction

Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST‐elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI)

Contact Info

Product

Resources

About